Car T Cell Therapy Market
CAR-T Cell Therapy Market Forecasts to 2030 - Global Analysis By Drug Type (Brexucabtagene Autoleucel, Axicabtagene Ciloleucel, Tisagenlecleucel and Other Drug Types), Target Antigen, Application, End User and By Geography
According to Stratistics MRC, the Global CAR-T Cell Therapy Market is accounted for $3.3 billion in 2023 and is expected to reach $21.8 billion by 2030 growing at a CAGR of 30.5% during the forecast period. CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy, is a groundbreaking form of immunotherapy used in the treatment of certain types of cancer. It involves genetically modifying a patient's own T cells (a type of immune cell) to express chimeric antigen receptors (CARs) on their surface. The process typically starts by collecting T cells from the patient's blood through a process called leukapheresis. These T cells are then genetically engineered in a laboratory to express specific receptors called CARs on their surface. These receptors are designed to recognize and bind to specific proteins, typically found on the surface of cancer cells.
According to the cancer data published by World Cancer Research Fund International, there were 474,519 new cases of leukemia, 176,404 new cases of multiple myeloma and 627,439 new cases of lymphoma worldwide in 2020.
Market Dynamics:
Driver:
Increasing prevalence of cancer
Despite the promising advancements in CAR-T technology, the rise in cancer incidence poses significant challenges. Factors such as aging populations, environmental factors, and lifestyle changes contribute to this trend. As the demand for effective cancer treatments grows, addressing this rising prevalence becomes imperative for healthcare providers and researchers in the field of CAR-T therapy. Thus, the market is experiencing a concerning trend with an increasing prevalence of cancer cases.
Restraint:
Limited number of approved therapies
In the rapidly evolving field of CAR-T cell therapy, only a limited number of treatments have gained approval. These therapies have shown remarkable efficacy in treating certain types of blood cancers, including leukemia and lymphoma. However, the market remains relatively constrained due to high costs, complex manufacturing processes, and the need for further research to expand indications and improve safety profiles.
Opportunity:
Advancements in technology
Advancements in CAR-T cell therapy have revolutionized cancer treatment, offering personalized immunotherapy solutions. Enhanced manufacturing techniques, such as lent viral vector design and automated cell processing systems, streamline production, improving scalability and reducing costs. Targeted modifications to CAR constructs enhance tumour specificity and reduce off-target effects, boosting therapeutic efficacy.
Threat:
High manufacturing costs
The market faces significant manufacturing costs, primarily due to the complex and labor-intensive process involved. Manufacturing CAR-T cells requires sophisticated cell engineering techniques, extensive quality control measures, and specialized infrastructure. Additionally, personalized nature of the therapy adds to the expenses, as each treatment is tailored to individual patients. These high costs pose challenges for widespread adoption and accessibility of CAR-T cell therapy, limiting its availability to a broader patient population.
Covid-19 Impact:
The COVID-19 pandemic has significantly impacted the CAR-T cell therapy market, causing disruptions in clinical trials, manufacturing, and patient access. Supply chain disruptions and reduced hospital capacity have delayed treatments and hindered market growth. Additionally, diverted resources and prioritization of COVID-19 care have diverted attention from CAR-T therapy development and deployment. Despite challenges, increased focus on immunotherapy and innovative treatments may drive market recovery and growth in the long term.
The tisagenlecleucel segment is expected to be the largest during the forecast period
The tisagenlecleucel segment is expected to be the largest during the forecast period. Engineered to target specific cancer cells, it has shown remarkable efficacy in patients with certain types of leukemia and lymphoma. Its approval marked a significant milestone in immunotherapy, offering new hope for patients who have exhausted conventional treatments. With its success, Tisagenlecleucel has quickly become a pivotal player in the CAR-T cell therapy market, driving advancements and further research in the field.
The lymphoma segment is expected to have the highest CAGR during the forecast period
The lymphoma segment is expected to have the highest CAGR during the forecast period driven by advancements in immunotherapy. CAR-T cell therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells. This personalized approach has shown promising results in various lymphoma subtypes, particularly in patients who have not responded to conventional treatments. With ongoing research and clinical trials, the market for therapy in lymphoma is poised for further growth.
Region with largest share:
North America is projected to hold the largest market share during the forecast period. With a focus on personalized medicine, CAR-T therapies are gaining traction for treating various types of cancers, including leukemia and lymphoma. The region's robust healthcare infrastructure, coupled with supportive regulatory frameworks, fosters market expansion. Moreover, collaborations between pharmaceutical companies and academic institutions contribute to accelerating innovation in this promising field, promising a bright outlook for the market.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period. The rising prevalence of cancer in countries, coupled with growing awareness and improved diagnosis, was creating a larger pool of patients who could potentially benefit from CAR-T cell therapy. There was a significant increase in the number of clinical trials for CAR-T cell therapies being conducted in countries. These trials were evaluating the safety and efficacy of various CAR-T treatments across different types of cancer, contributing to the advancement of the field in the region.
Key players in the market
Some of the key players in CAR-T Cell Therapy market include Gilead Sciences Inc., Bristol-Myers Squibb, Novartis AG, Cartesian Therapeutics Inc., Merck & Co. Inc., Intellia Therapeutics, Juno Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics Inc., Autolus Therapeutics, Caribou Biosciences Inc., Miltenyi Biotech, Celgene Corporation, Aurora Biopharma Inc. and Pfizer, Inc.
Key Developments:
In December 2023, Bristol-Myers Squibb announced that it received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
In May 2023, Autolus Therapeutics plc announced that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress.
Drug Types Covered:
• Brexucabtagene Autoleucel
• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Other Drug Types
Target Antigens Covered:
• CD19
• B-Cell Maturation Antigen (BCMA)
• GD2
• CD20
• Other Target Antigens
Applications Covered:
• Acute Lymphocytic Leukemia
• Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hepatocellular Carcinoma
• Colorectal Cancer
• Other Applications
End Users Covered:
• Cancer Treatment Centers
• Hospitals
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global CAR T-Cell Therapy Market, By Drug Type
5.1 Introduction
5.2 Brexucabtagene Autoleucel
5.3 Axicabtagene Ciloleucel
5.4 Tisagenlecleucel
5.5 Other Drug Types
6 Global CAR T-Cell Therapy Market, By Target Antigen
6.1 Introduction
6.2 CD19
6.3 B-Cell Maturation Antigen (BCMA)
6.4 GD2
6.5 CD20
6.6 Other Target Antigens
7 Global CAR T-Cell Therapy Market, By Application
7.1 Introduction
7.2 Acute Lymphocytic Leukemia
7.3 Lymphoma
7.4 Chronic Lymphocytic Leukemia
7.5 Follicular Lymphoma
7.6 Hepatocellular Carcinoma
7.7 Colorectal Cancer
7.8 Other Applications
8 Global CAR T-Cell Therapy Market, By End User
8.1 Introduction
8.2 Cancer Treatment Centers
8.3 Hospitals
8.4 Other End Users
9 Global CAR T-Cell Therapy Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Gilead Sciences Inc.
11.2 Bristol-Myers Squibb
11.3 Novartis AG
11.4 Cartesian Therapeutics Inc.
11.5 Merck & Co. Inc.
11.6 Intellia Therapeutics
11.7 Juno Therapeutics Inc.
11.8 Bluebird Bio Inc.
11.9 Sorrento Therapeutics Inc.
11.10 Autolus Therapeutics
11.11 Caribou Biosciences Inc.
11.12 Miltenyi Biotech
11.13 Celgene Corporation
11.14 Aurora Biopharma Inc.
11.15 Pfizer, Inc.
List of Tables
1 Global CAR T-Cell Therapy Market Outlook, By Region (2021-2030) ($MN)
2 Global CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
3 Global CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
4 Global CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
5 Global CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
6 Global CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
7 Global CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
8 Global CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
9 Global CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
10 Global CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
11 Global CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
12 Global CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
13 Global CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
14 Global CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
15 Global CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
16 Global CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
17 Global CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
18 Global CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
19 Global CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
20 Global CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
21 Global CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
22 Global CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
23 Global CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
24 Global CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
25 North America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
26 North America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
27 North America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
28 North America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
29 North America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
30 North America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
31 North America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
32 North America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
33 North America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
34 North America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
35 North America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
36 North America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
37 North America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
38 North America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
39 North America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
40 North America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
41 North America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
42 North America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
43 North America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
44 North America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
45 North America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
46 North America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
47 North America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
48 North America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
49 Europe CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
50 Europe CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
51 Europe CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
52 Europe CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
53 Europe CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
54 Europe CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
55 Europe CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
56 Europe CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
57 Europe CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
58 Europe CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
59 Europe CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
60 Europe CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
61 Europe CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
62 Europe CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
63 Europe CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
64 Europe CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
65 Europe CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
66 Europe CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
67 Europe CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
68 Europe CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
69 Europe CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
70 Europe CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
71 Europe CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
72 Europe CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
73 Asia Pacific CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
74 Asia Pacific CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
75 Asia Pacific CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
76 Asia Pacific CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
77 Asia Pacific CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
78 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
79 Asia Pacific CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
80 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
81 Asia Pacific CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
82 Asia Pacific CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
83 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
84 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
85 Asia Pacific CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
86 Asia Pacific CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
87 Asia Pacific CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
88 Asia Pacific CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
89 Asia Pacific CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
90 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
91 Asia Pacific CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
92 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
93 Asia Pacific CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
94 Asia Pacific CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
95 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
96 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
97 South America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
98 South America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
99 South America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
100 South America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
101 South America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
102 South America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
103 South America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
104 South America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
105 South America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
106 South America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
107 South America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
108 South America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
109 South America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
110 South America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
111 South America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
112 South America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
113 South America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
114 South America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
115 South America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
116 South America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
117 South America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
118 South America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
119 South America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
120 South America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
121 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
122 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
123 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
124 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
125 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
126 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
127 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
128 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
129 Middle East & Africa CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
130 Middle East & Africa CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
131 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
132 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
133 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
134 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
135 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
136 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
137 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
138 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
139 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
140 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
141 Middle East & Africa CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
142 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
143 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
144 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
